SrasV1, 2020, Analysis, bibRecord, 000870

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.

Identifieur interne : 000870 ( 2020/Analysis ); précédent : 000869; suivant : 000871

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.

Auteurs : Leo F. Buckley ; Judy W M. Cheng ; Akshay Desai

Source :

Journal of cardiovascular pharmacology [ 1533-4023 ] ; 2020.

RBID : pubmed:32301766

Abstract

Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.

DOI: 10.1097/FJC.0000000000000840
PubMed: 32301766

Affiliations:

Links to Exploration step

pubmed:32301766

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.</title>
<author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name>
<affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name>
<affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name>
<affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32301766</idno>
<idno type="pmid">32301766</idno>
<idno type="doi">10.1097/FJC.0000000000000840</idno>
<idno type="wicri:Area/PubMed/Corpus">000058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000058</idno>
<idno type="wicri:Area/PubMed/Curation">000058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000058</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000688</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000688</idno>
<idno type="wicri:Area/Ncbi/Merge">003B37</idno>
<idno type="wicri:Area/Ncbi/Curation">003B37</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B37</idno>
<idno type="wicri:Area/Main/Merge">000870</idno>
<idno type="wicri:Area/Main/Curation">000870</idno>
<idno type="wicri:Area/Main/Exploration">000870</idno>
<idno type="wicri:Area/2020/Extraction">000870</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.</title>
<author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name>
<affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name>
<affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name>
<affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital.</nlm:affiliation>
<wicri:noCountry code="subField">Brigham and Women's Hospital</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of cardiovascular pharmacology</title>
<idno type="eISSN">1533-4023</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name>
<name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name>
<name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000870 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000870 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32301766
   |texte=   Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32301766" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.